Key facts
- DUB Therapeutics’s last known valuation is $13.0M (May 2025).
- It has raised $1.0M; the latest was Early Stage VC ($1.0M) in May 2025.
- Notable investors include CNY Biotech Accelerator, Excell Partners.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for DUB Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for DUB Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DUB Therapeutics
Developer of a global life sciences and sourcing platform designed to use self-delivering siRNA technology to improve health and well-being. The company's technology addresses fibrotic diseases and enhances the quality of life of patients suffering from fibrosis, starting with ocular diseases, develops therapeutics, like siRNA, and is working to improve health outcomes in patients, helping patients by developing programs on ocular and dermal wound healing.
- Sector
- Healthcare
- HQ
- Syracuse, NY, United States
- Founded
- 2022
- Employees
- 4
- Website
- dubtx.com/
- Ownership
- Privately Held (backing)
DUB Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DUB Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DUB Therapeutics in its N-PORT filings yet. We sweep new filings monthly.